Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers

Cancer Gene Therapy

Volumn 9, Issue 12, 2002, Pages 1001-1012

  Zeh, Herbert J ^a   Bartlett, David L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer; Gene therapy; Replicating; Vaccinia; Vector

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CHEMOKINE; CHEMOKINE BINDING PROTEIN; COMPLEMENT; COMPLEMENT BINDING PROTEIN; GAMMA INTERFERON; GROWTH FACTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; ONCOLYTIC VIRUS; THYMIDINE KINASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VACCINIA GROWTH FACTOR; VIRUS VECTOR; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BYSTANDER EFFECT; CANCER CELL; CANCER THERAPY; CYTOLYSIS; DELETION MUTANT; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFORMATION; HYPERTHERMIC THERAPY; IMMUNOSTIMULATION; MOUSE; NONHUMAN; POXVIRUS; POXVIRUS VECTOR; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR NECROSIS; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS MUTANT; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; ANTIBODY SPECIFICITY; GENE VECTOR; GENETIC ENGINEERING; GENETICS; HUMAN; IMMUNOLOGY; METHODOLOGY; MUTATION; NEOPLASM; VIROLOGY;

ANIMALIA; POXVIRIDAE; PRIMATES; VACCINIA VIRUS;

ANIMALS; BYSTANDER EFFECT; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; HYPERTHERMIA, INDUCED; MUTATION; NEOPLASMS; ORGAN SPECIFICITY; PEPTIDES; POXVIRIDAE; THYMIDINE KINASE; VIRUS REPLICATION;

EID: 0036905081     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700549     Document Type: Review

References (58)

1. Fenner F. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. Lippincott-Raven: Philadelphia; 1996: 2673-2700.
2. Fentiman IS, Rubens RD, Hayward JI. A comparison of intracavitary talcum and tetracycline for the control of pleural effusion secondary to breast cancer. Eur J Cancer Clin Oncol. 1986;22:1079.
3. Fenner F, Wittek R, Dumbell KR. The Orthopoxviruses. Academic Press: New York; 1989:143-170.
4. Antoine G, Scheiflinger F, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: Comparison with other orthopoxviruses. Virology. 1998;242: 365-396.
5. Goebel SJ, Johnson GP, Perkus ME, Davis SW, Winslow JP, Paoletti E. The complete DNA sequence of vaccinia virus. Virology. 1990;179:247-266.
6. Hsiao JC, Chung CS, Chang W. Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol. 1999;73:8750-8761.
7. Chung CS, Hsiao JC, Chang YS, Chang W. A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J Virol. 1998;72:1577-1585.
8. Moss B, Earl PL. Expression of proteins in mammalian cells using vaccinia viral vectors. Curr Prot Mol Biol. 1998;43:16.
9. McIntosh AAG, Smith GL. Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus. J Virol. 1996;70:272-281.
10. Seet BT, McFadden G. Viral chemokine-binding proteins. J Leukoc Biol. 2002;72:24-34.
11. Alcami A, Symons JA, Collins PD, Williams TJ, Smith GL. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J Immunol. 1998;160:624-633.
12. Mahalingam S, Karupiah G. Modulation of chemokines by poxvirus infections. Curr Opin Immunol. 2000;12:409-412.
13. Symons JA, Alcami A, Smith GL. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell. 1995;81:551-560.
14. Najarro P, Traktman P, Lewis JA. Vaccinia virus blocks gamma interferon signal transduction: Viral VH1 phosphatase reverses Stat1 activation. J Virol. 2001;75:3185-3196.
15. Smith V, Bryant NA, Alcami A. Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins. J Gen Virol. 2000;81:1223-1230.
16. Calderara S, Xiang Y, Moss B. Orthopoxvirus IL-18 binding proteins: Affinities and antagonist activities. Virology. 2001;279: 22-26.
17. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response. Immunity. 1999;10:127-136.
18. Engelstad M, Howard ST, Smith GL. A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology. 1992;188:801-810.
19. Bowie A, Kiss-Toth E, Symons JA, Smith GL, Dower SK, O'Neill LA. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci USA. 2000;97:10162-10167.
20. Howard ST, Chan YS, Smith GL. Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family. Virology. 1991;180:633-647.
21. Smith GL, Howard ST, Chan YS. Vaccinia virus encodes a family of genes with homology to serine proteinase inhibitors. J Gen Virol. 1989;70:2333-2343.
22. Sutter G, Moss B. Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. Dev Biol Stand. 1995;84:195-200.
23. Blanchard TJ, Alcami A, Andrea P, Smith GL. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine. J Gen Virol. 1998;79:1159-1167.
24. Deonarain R, Alcami A, Alexiou M, Dallman MJ, Gewert DR, Porter AC. Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon. J Virol. 2000;74:3404-3409.
25. van Den Broek M, Bachmann MF, Kohler G, Barner M, Escher R, Zinkernagel R, Kopf M. IL-4 and IL-10 antagonize IL-12-mediated protection against acute vaccinia virus infection with a limited role of IFN-gamma and nitric oxide synthetase 2. J Immunol. 2000;164:371-378.
26. Whitman ED, Tsung K, Paxson J, Norton JA. In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery. 1994;116:183-188.
27. Moss B, Carroll MW, Wyatt LS, et al. Host range restricted, non-replicating vaccinia virus vectors as vaccinia candidates, in Design and Production of Vaccines. New York: Plenum Press; 1996:7-13.
28. Ricketts TF. Diagnosis of Smallpox. London: Cassell and Company; 1966:6-13.
29. Neeman M, Abramovitch R, Schiffenbauer YS, Tempel C. Regulation of angiogenesis by hypoxic stress: From solid tumours to the ovarian follicle. Int J Exp Pathol. 1997;78:57-70.
30. McCart JA, Hu YK, Alexander HR, Libutti SK, Moss B, Bartlett DL. A combined thymidine kinase/vaccinia growth factor deleted vaccinia virus as a vector for cancer gene therapy. Proc Am Soc Gene Ther. 1999;2:160.
31. Puhlmann M, Brown CK, Gnant M, et al. Vaccinia as a vector for tumor directed gene therapy: Biodistribution of a thymidine kinase deleted mutant. Cancer Gene Ther. 2000;7:66-73.
32. Gnant MF, Noli LA, Irvine KR, et al. Tumor specific gene delivery using recombinant vaccinia virus in a rabbit model of unresectable liver metastases - Pattern of gene expression, vector elimination and immune response. J Natl Cancer Inst. 1999;91:1744-1750.
33. McCart JA, Puhlmann M, Lee J, et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther. 2000;7:1217-1223.
34. Gnant MFX, Puhlmann M, Alexander HR Jr, Bartlett DL. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor specific gene expression and prolongation of survival in mice. Cancer Res. 1999;59:3396-3404.
35. Puhlmann M, Gnant M, Brown CK, Alexander HR, Bartlett DL. Thymidine kinase deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor directed gene therapy. Hum Gene Ther. 1999;10:649-657.
36. McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001;61:8751-8757, 12-15 (Reference Type: Generic).
37. Buller RML, Chakrabarti S, Cooper JA, Twardzik DR, Moss B. Deletion of the vaccinia virus growth factor gene reduces virus virulence. J Virol. 1988;62:866-874.
38. Bischoff JR, Kim DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [see comments]. Science. 1996;274:373-376.
39. Ray C, Black RA, Kronheim SR, et al. Viral inhibition of inflammation: Cowpox virus encodes an inhibitor of the interleukin-1α converting enzyme. Cell. 1992;69:597-604.
40. r 385 and 40K, intracellular polypeptides that do not affect virus virulence in a murine intranasal model. Virology. 1995;206:136-147.
41. Shisler JL, Isaacs SN, Moss B. Vaccinia virus serpin-1 deletion mutant exhibits a host range defect characterized by low levels of intermediate and late mRNAs. Virology. 1999;262:298-311.
42. Perkus ME, Goebel SJ, Davis SW, et al. Vaccinia virus host range genes. Virology. 1990;179:276-286.
43. Chung CS, Vasilevskaya IA, Wang SC, Bair CH, Chang W. Apoptosis and host restriction of vaccinia virus in RK13 cells. Virus Res. 1997;52:121-132.
44. Oguiura N, Spehner D, Drillien R. Detection of a protein encoded by the vaccinia virus C7L open reading frame and study of its effect on virus multiplication in different cell lines. J Gen Virol. 1993;74:1409-1413.
45. Ramsey-Ewing AL, Moss B. Complementation of a vaccinia virus host-range KIL gene deletion by the nonhomologous CP77 gene. Virology. 1996;222:75-86.
46. Galmiche MC, Rindisbacher L, Wels W, Wittek R, Buchegger F. Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting. J Gen Virol. 1997;78: 3019-3027.
47. Hu Y, Lee J, McCart JA, et al. Yaba like disease virus: An alternating replicating pox vector for cancer gene therapy. J Virol. 2001;75:10300-10308.
48. Sharma DP, Ramsay AJ, Maguire DJ, Rolph MS, Ramshaw IA. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J Virol. 1996;70:7103-7107.
49. Perera LP, Goldman CK, Waldmann TA. Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice. Proc Natl Acad Sci USA. 2001;98:5146-5151.
50. Karupiah G, Woodhams CE, Blanden RV, Ramshaw IA. Immunobiology of infection with recombinant vaccinia virus encoding murine IL-2. Mechanisms of rapid viral clearance in immunocompetent mice. J Immunol. 1991;147:4327-4332.
51. Ruby J, Bluethmann H, Aguet M, Ramshaw IA. CD40 ligand has potent antiviral activity. Nat Med. 1995;1:437-441.
52. Sambhi SK, Kohonen-Corish MR, Ramshaw IA. Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo. Proc Natl Acad Sci USA. 1991;88:4025-4029.
53. Ramirez JC, Gherardi MM, Rodriguez D, Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol. 2000;74:7651-7655.
54. Gherardi MM, Ramirez JC, Rodriguez D, et al. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. J Immunol. 1999;162:6724-6733.
55. Lattime EC, Lee SS, Eisenlohr LC, Mastrangelo MJ. In situ cytokine gene transfection using vaccinia virus vectors. Semin Oncol. 1996;23:88-100.
56. Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 1998;6:409-422.
57. + T lymphocytes. Proc Natl Acad Sci. 1999;96:2982-2987.
58. Rosenberg SA, Blaese RM, Brenner MK, et al. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1999;10: 3067-3123.